Relation of serum heart type fatty acid binding protein to left ventricular diastolic dysfunction in patients with type 2 diabetes and early diabetic kidney disease

Author(s):  
Talaat Abdelaaty ◽  
Eman Morsy ◽  
Mohammed Rizq ◽  
Ahmed Shokry ◽  
Ahmed Abdelhameid ◽  
...  
2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Mei-Zhen Wu ◽  
Chi-Ho Lee ◽  
Yan Chen ◽  
Shuk-Yin Yu ◽  
Yu-Juan Yu ◽  
...  

Abstract Background The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. Here we investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM. Methods Circulating AFABP levels were measured in 176 T2DM patients without cardiovascular diseases (CVD) at baseline. All participants received detailed transthoracic echocardiography both at baseline and after 1 year. Multivariable linear and Cox regression analyses were used to evaluate the associations of circulating AFABP levels with changes in echocardiography parameters and incident major adverse cardiovascular events (MACE), respectively. Results The median duration between baseline and follow-up echocardiography assessments was 28 months. Higher sex-specific AFABP quartiles at baseline were associated with increase in LV mass and worsening of average E/e′ (all P < 0.01). Multivariable linear regression demonstrated that AFABP in the highest quartile was independently associated with both increase in LV mass (β = 0.89, P < 0.01) and worsening of average E/e′ (β = 0.57, P < 0.05). Moreover, multivariable Cox regression analysis showed that elevated baseline circulating AFABP level independently predicted incident MACE (HR 2.65, 95% CI 1.16–6.05, P < 0.05) after adjustments for age, sex, body mass index, glycated haemoglobin, hypertension, dyslipidemia and presence of chronic kidney disease. Conclusion Circulating AFABP level at baseline predicted the development of LV hypertrophy, diastolic dysfunction and MACE in T2DM patients without CVD.


2018 ◽  
Vol 64 (10) ◽  
pp. 1496-1504 ◽  
Author(s):  
Chi Ho Lee ◽  
Chloe Y Y Cheung ◽  
Yu Cho Woo ◽  
David T W Lui ◽  
Michele M A Yuen ◽  
...  

AbstractINTRODUCTIONRaised circulating adipocyte fatty acid–binding protein (AFABP) concentrations are associated with various adverse health conditions. However, their relationship with mortality remains to be defined, especially in view of the sexual dimorphism of circulating AFABP concentrations. Here we investigated prospectively whether serum AFABP concentrations predict multiple mortality outcomes in men and women alike, using a large clinic-based cohort of individuals with type 2 diabetes, a condition with raised AFABP concentrations.METHODSBaseline serum AFABP concentrations were measured in 5305 research participants with a monoclonal antibody-based sandwich immunoassay. The role of circulating AFABP concentrations in predicting mortality outcomes was evaluated by multivariable Cox regression analysis.RESULTSAmong the 5305 participants (59% men) in this study, over a median follow-up of 5 years, there were 512 deaths (19.3 deaths per 1000 person-years). Circulating AFABP concentrations, with higher levels in women at baseline, predicted all-cause mortality (P &lt; 0.001), cardiovascular mortality (P = 0.037), and infection-related deaths (P &lt; 0.002) among all participants. In sex-specific analyses, circulating AFABP concentration was an independent predictor of all-cause mortality in both men and women and a predictor of cancer-related deaths and infection-related deaths in men only. Furthermore, the addition of serum AFABP concentrations improved the time-dependent c statistics in predicting all-cause mortality in participants with type 2 diabetes (P = 0.008).CONCLUSIONSCirculating AFABP concentration was an independent predictor of various mortality outcomes in type 2 diabetes over and above known risk factors of reduced survival in men and women. The role of AFABP as a prognostic biomarker and therapeutic target warrants further investigation.


2017 ◽  
Vol 9 (4) ◽  
pp. 366-373 ◽  
Author(s):  
Hiroyuki Ito ◽  
Hitomi Yamashita ◽  
Mina Nakashima ◽  
Akifusa Takaki ◽  
Chiduko Yukawa ◽  
...  

2019 ◽  
Vol 13 (3) ◽  
pp. 283
Author(s):  
Lili Huang ◽  
Weizhuo Dominique Tan ◽  
Chengjian Wang ◽  
Zhengxiang Huang ◽  
Johannes D. Veldhuis ◽  
...  

Metabolism ◽  
2019 ◽  
Vol 96 ◽  
pp. 12-21 ◽  
Author(s):  
Ricardo Rodríguez-Calvo ◽  
Josefa Girona ◽  
Marina Rodríguez ◽  
Sara Samino ◽  
Emma Barroso ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document